Enhanced antimalarial activity of lumefantrine nanopowder prepared by wet-milling DYNO MILL technique

Colloids and Surfaces B: Biointerfaces

Volumn 95, Issue , 2012, Pages 16-22

  Gahoi, Sachin ^a,b   Jain, Gaurav K ^c   Tripathi, Renu ^d   Pandey, Swaroop K ^d   Anwar, Mohammed ^c   Warsi, Musarrat H ^c   Singhal, Mayank ^c   Khar, Roop K ^c   Ahmad, Farhan J ^c  

^a SINGHANIA UNIVERSITY   (India)

^b Matrix Laboratories Limited   (India)

^c HAMDARD UNIVERSITY   (India)

^d CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Antimalarial; Dissolution rate; Lumefantrine; Nanopowder; Wet milling

Indexed keywords

ANTIMALARIAL; DISSOLUTION RATES; LUMEFANTRINE; NANO POWDERS; WET MILLING;

BIOCHEMISTRY; DISSOLUTION; MILLING (MACHINING);

NANOSTRUCTURED MATERIALS;

BENFLUMETOL; CHLOROQUINE; HYDROXYPROPYLMETHYLCELLULOSE; POLYSORBATE 80;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG STABILITY; IC 50; IN VIVO STUDY; MOUSE; NANOPHARMACEUTICS; NANOPOWDER; NANOSUSPENSION; NONHUMAN; PARASITE CLEARANCE; PARASITEMIA; PARTICLE SIZE; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; PLASMODIUM YOELII INFECTION; PLASMODIUM YOELII NIGERIENSIS; POWDER; PRIORITY JOURNAL; SURVIVAL TIME; SUSPENSION; WET MILLING;

ANIMALS; ANTIMALARIALS; ETHANOLAMINES; FLUORENES; MALARIA, FALCIPARUM; MICE; NANOPARTICLES; PARASITIC SENSITIVITY TESTS; PARTICLE SIZE; PLASMODIUM FALCIPARUM; SURFACE PROPERTIES; WETTABILITY;

EID: 84860549641     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2012.01.047     Document Type: Article

References (30)

1. Merisko-Liversidge E.M., Liversidge G.G. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol. 2008, 36:43-48.
2. Lipinski C. Poor aqueous solubility-an industry wide problem in drug delivery. Am. Pharm. Rev. 2002, 5:82-85.
3. Stella V.J., Rajewski R.A. Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 1997, 14:556-567.
4. Lawrence M.J., Rees G.D. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 2000, 45:89-121.
5. Nakano M. Places of emulsions in drug delivery. Adv. Drug Deliv. Rev. 2000, 45:1-4.
6. Kesisoglou F., Panmai S., Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 2007, 59:631-644.
7. Joshi V., Dwivedi S., Ward G.H. Increase in the specific surface area of budesonide during storage postmicronization. Pharm. Res. 2002, 19:7-12.
8. Van N.T., Brennan K., Van M.G., Blaton N., Kinget R., Augustijns P. Improvement of the dissolution rate of artemisinin by means of supercritical fluid technology and solid dispersions. Int. J. Pharm. 2003, 254:173-181.
9. Lee C.C., Chan L.W., Heng P.W. Use of a fluidized bed hammer mill for size reduction and classification: effects of process variables and starting materials on the particle size distribution of milled lactose batches. Pharm. Dev. Technol. 2003, 8:431-442.
10. Chingunpitak J., Puttipipatkhachorn S., Tozuka Y., Moribe K., Yamamot K. Micronization of dihydroartemisinin by rapid expansion of supercritical solutions. Drug Dev. Ind. Pharm. 2008, 34:609-617.
11. Saleki-Guerrero A., Ahlneck C., Zografi G. Assessment of disorder in crystalline solids. Int. J. Pharm. 1994, 101:144.
12. Merisko-Liversidge E., Liversidge G.G., Cooper E.R. Nanosizing: a formulation approach for poorly-water soluble compounds. Eur. J. Pharm. Sci. 2003, 18:113-120.
13. Inkyo M., Tahara T. Dispersion of agglomerated nanoparticles by fine Beads mill. J. Soc. Powder Technol. Jpn. 2004, 41:578-585.
14. Rogers T.L., Gillespie I.B., Hitt J.E., Fransen K.L., Crowl C.A., Tucker C.J., Kupperblatt G.B., Becker J.N., Wilson D.L., Todd C., Broomall C.F., Evans J.C., Elder E.J. Development and characterization of a scalable controlled precipitation process to enhance the dissolution of poorly water-soluble drugs. Pharm. Res. 2004, 11:2048-2057.
15. Mittapalli P.K., Yamasani M.R., Shashank A. Improved bioavailability of albendazole following oral administration of nanosuspension in rats. Curr. Nanosci. 2007, 3:191-194.
16. Mittapalli P.K., Yamasani M.R., Shashank A. Formulation of nanosuspensions of albendazole for oral administration. Curr. Nanosci. 2008, 4:53-58.
17. Tanaka Y., Inkyo M., Yumoto R., Nagai J., Takano M., Nagata S. Nanoparticulation of poorly water soluble drugs using a wet-mill process and physicochemical properties of the nanopowders. Chem. Pharm. Bull. 2009, 57:1050-1057.
18. Van V.M., Brockman A., Gemperli B. Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob. Agents Chemother. 1998, 42:135-139.
19. Ezzet F., Van Vugt M., Nosten F., Looareesuwan S., White N.J. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother. 2000, 44:697-704.
20. Trager W., Jansen J.B. Human malaria parasites in continuous culture. Science 1976, 193:673-675.
21. Johnson J.D., Richard A.D., Lucia G., Miriam L., Norma E.R., Norman C.W. Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. Antimicrob. Agents Chemother. 2007, 51:1926-1933.
22. Madapa S., Tusi Z., Mishra A., Srivastava K., Pandey S.K., Tripathi R., Puri S.K., Batra S. Search for new pharmacophores for antimalarial activity. Part II. Synthesis and antimalarial activity of new 6-ureido-4-anilinoquinazolines. Bioorg. Med. Chem. 2009, 17:222-234.
23. Galindo-Rodriguez S.A., Allemann E., Fessi H., Doelker E. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit. Rev. Ther. Drug Carrier Syst. 2005, 22:419-464.
24. Hecq J., Deleers M., Fanara D., Vranckx H., Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm. 2005, 299:167-177.
25. Bilati U., Allémann E., Doelker E. Poly(d,l-lactide-co-glycolide) protein-loaded nanoparticles prepared by the double emulsion method-processing and formulation issues for enhanced entrapment efficiency. J. Microencapsul. 2005, 22:205-214.
26. Lee J. Drug nano- and microparticles processed into solid dosage forms: Physical properties. J. Pharm. Sci. 2003, 92:2057-2066.
27. Hecq J., Deleers M., Fanara D., Vranckx H., Boulanger P., Le Lamer S., Amighi K. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur. J. Pharm. Biopharm. 2006, 64:360-368.
28. Lee J., Cheng Y. Critical freezing rate in freeze drying nanocrystal dispersions. J. Control. Release 2006, 111:185-192.
29. Chokshi R.J., Sandhu H.K., Iyer R.M., Shah N.H., Malick A.W., Zia H. Characterization of physicomechanical properties of indomethacin and polymers to assess their suitability for hotmelt extrusion process as a means to manufacture solid dispersion/solution. J. Pharm. Sci. 2005, 94:2463-2474.
30. Noyes A.A., Whitney W.R. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 1897, 19:930-934.